These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H. Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [Abstract] [Full Text] [Related]
6. The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis. Visser ME, Texeira-Swiegelaar C, Maartens G. Int J Tuberc Lung Dis; 2004 Feb; 8(2):260-2. PubMed ID: 15139457 [Abstract] [Full Text] [Related]
7. [Standardized controlled antitubercular therapy and results in 755 patients]. Wiesner B, Cramer G, Hamel U, Roth G. Z Erkr Atmungsorgane; 1991 Feb; 177(1-2):71-5. PubMed ID: 1808855 [Abstract] [Full Text] [Related]
11. [Preliminary results of initial short-term chemotherapy with INH, RMP and EMB in intermittent and biphasic administration (the 3 plus 6 experiment)]. Anastasatu C, Bercea O, Barcan F, Stinghe R, Dinulică E, Marcovici M, Cristea M, Cărpinişan L, Gheorghiu M, Iancovici O, Ghinescu S. Ftiziologia; 1974 May; 23(3):253-64. PubMed ID: 4842931 [No Abstract] [Full Text] [Related]
19. Rationale for chemotherapy of tuberculosis and current recommendations. Kumar L. Indian Pediatr; 1992 Nov; 29(11):1337-9. PubMed ID: 1294486 [No Abstract] [Full Text] [Related]